Zhang Chongyang, He Jiazhen, Xiong Dan, Mei Yi, Zhu Yao, Deng Pan, Duan Yang
Department of Cardiology, Shijingshan Teaching Hospital of Capital Medical University, Beijing Shijingshan Hospital, Beijing, 100043, China.
Department of Cardiovascular, The Eighth Hospital of Wuhan, Wuhan, 430012, China.
J Cardiothorac Surg. 2025 Jan 10;20(1):53. doi: 10.1186/s13019-024-03221-9.
MicroRNAs (miRNAs) are closely related to cardiovascular diseases, including chronic heart failure (CHF). Endothelial dysfunction can lead to heart failure. The purpose of this study was to evaluate the clinical significance of miR-1285-3p in CHF patients, with the aim of identifying a novel and effective biomarker for CHF. At the same time, we investigated the effect of miR-1285-3p on vascular endothelial cells.
Total RNA was extracted from plasma samples of 106 CHF patients and 106 healthy individuals. Quantitative Real-time PCR (qRT-PCR) was used to detect the expression of miR-1285-3p. The diagnostic accuracy of miR-1285-3p was tested by receiver operating characteristic (ROC) curve. Evaluated the related risk factors of CHF using logistic analysis. The proliferation and apoptosis of human umbilical vein endothelial cells (HUVECs) were detected by transfecting miR-1285-3p mimic or miR-1285-3p inhibitor in vitro using CCK8 and flow cytometry. Effect of miR-1285-3p on the angiogenesis of HUVECs were detected by in vitro angiogenesis assay.
miR-1285-3p is upregulated in CHF patients, demonstrating the ability to distinguish CHF patients from healthy individuals, with high sensitivity (83.0%) and specificity (93.4%). In vitro experiments revealed that transfection of miR-1285-3p mimic inhibited endothelial cell proliferation, accelerated apoptosis, and inhibited endothelial cell angiogenesis, which was reversed by transfection with miR-1285-3p inhibitor.
miR-1285-3p is upregulated in CHF and may serve as a new effective biomarker for CHF diagnosis, which can inhibit HUVECs angiogenesis.
微小RNA（miRNA）与心血管疾病密切相关，包括慢性心力衰竭（CHF）。内皮功能障碍可导致心力衰竭。本研究旨在评估miR-1285-3p在CHF患者中的临床意义，以寻找一种新的、有效的CHF生物标志物。同时，我们研究了miR-1285-3p对血管内皮细胞的影响。
从106例CHF患者和106例健康个体的血浆样本中提取总RNA。采用定量实时聚合酶链反应（qRT-PCR）检测miR-1285-3p的表达。通过受试者工作特征（ROC）曲线检验miR-1285-3p的诊断准确性。采用逻辑分析评估CHF的相关危险因素。体外转染miR-1285-3p模拟物或miR-1285-3p抑制剂，使用CCK8和流式细胞术检测人脐静脉内皮细胞（HUVECs）的增殖和凋亡。通过体外血管生成试验检测miR-1285-3p对HUVECs血管生成的影响。
CHF患者中miR-1285-3p上调，具有区分CHF患者和健康个体的能力，敏感性高（83.0%），特异性强（93.4%）。体外实验表明，转染miR-1285-3p模拟物可抑制内皮细胞增殖，加速凋亡，并抑制内皮细胞血管生成，而转染miR-1285-3p抑制剂可逆转这一作用。
CHF患者中miR-1285-3p上调，可能作为CHF诊断的一种新的有效生物标志物，可抑制HUVECs血管生成。
